# Asthma & COPD Exacerbation â€“ Clinical Call Protocol

**Guidelines Referenced:**  
Global Initiative for Asthma (GINA) 2023 Guidelines, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Report, British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN) 2019 British Guideline on the Management of Asthma

**Official Sources:**  
https://ginasthma.org/2023-gina-main-report/  
https://goldcopd.org/2023-gold-report-2/  
https://www.brit-thoracic.org.uk/quality-improvement/guidelines/asthma/

## CARD INTERFACE LAYOUT

### Card 0 â€“ Dynamic Action Card (Node Dependent)

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ SEVERE ASTHMA EXACERBATION                                  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“± CALLED BY: ED RN, Room 12                               â”‚
â”‚ Patient: 28yo F with known asthma, worsening SOB           â”‚
â”‚                                                           â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                        â”‚
â”‚ â”‚     IMMEDIATE TREATMENT         â”‚                        â”‚
â”‚ â”‚ â˜‘ Albuterol 5mg neb x3 started â”‚ [q20min x3 doses]      â”‚
â”‚ â”‚ â˜‘ Ipratropium 0.5mg added      â”‚ [Synergistic effect]   â”‚
â”‚ â”‚ â˜‘ Methylpred 125mg IV given    â”‚ [Anti-inflammatory]    â”‚
â”‚ â”‚ â˜‘ O2 applied - SpO2 95%        â”‚ [4L NC titrated]       â”‚
â”‚ â”‚ â˜ Magnesium 2g ordered         â”‚ [For severe cases]     â”‚
â”‚ â”‚ â˜ ABG if not improving         â”‚ [Assess ventilation]   â”‚
â”‚ â”‚ â˜ Continuous albuterol         â”‚ [If poor response]     â”‚
â”‚ â”‚                                â”‚                        â”‚
â”‚ â”‚ Reassess in 30 minutes          â”‚                        â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                        â”‚
â”‚                                                           â”‚
â”‚ VITALS: BP 138/84, HR 118, RR 28, SpO2 95% on 4L, T 37.2Â°Câ”‚
â”‚                                                           â”‚
â”‚ SEVERITY ASSESSMENT:                                       â”‚
â”‚ â€¢ PEFR: 180 L/min (40% predicted) - SEVERE                â”‚
â”‚ â€¢ Speaking: Phrases only                                   â”‚
â”‚ â€¢ Pulsus paradoxus: >15 mmHg                              â”‚
â”‚ â€¢ Accessory muscle use: Present                           â”‚
â”‚                                                           â”‚
â”‚ ğŸš¨ SEVERE EXACERBATION - Monitor closely for deterioration â”‚
â”‚ Previous ICU admission 2 years ago for status asthmaticus  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Example - COPD Exacerbation Node:**

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ COPD EXACERBATION (AECOPD)                                  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ Patient: 68yo M with severe COPD (FEV1 35%), increased SOB  â”‚
â”‚                                                           â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                        â”‚
â”‚ â”‚     COPD-SPECIFIC TREATMENT     â”‚                        â”‚
â”‚ â”‚ â˜‘ O2 target SpO2 88-92%         â”‚ [Controlled O2 therapy]â”‚
â”‚ â”‚ â˜‘ Albuterol/Ipratropium neb     â”‚ [Dual bronchodilator]  â”‚
â”‚ â”‚ â˜‘ Prednisolone 30mg PO          â”‚ [5-day course]         â”‚
â”‚ â”‚ â˜‘ Antibiotics if purulent       â”‚ [Azithromycin 500mg]   â”‚
â”‚ â”‚ â˜ NIV consideration             â”‚ [If pH 7.25-7.35]     â”‚
â”‚ â”‚ â˜ Aminophylline if severe       â”‚ [Loading dose]         â”‚
â”‚ â”‚                                â”‚                        â”‚
â”‚ â”‚ Home O2: 2L continuous          â”‚                        â”‚
â”‚ â”‚ Smoking: 45 pack-year history   â”‚                        â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                        â”‚
â”‚                                                           â”‚
â”‚ VITALS: BP 148/88, HR 102, RR 26, SpO2 89% on 2L          â”‚
â”‚                                                           â”‚
â”‚ ANTHONISEN CRITERIA (2/3 present):                        â”‚
â”‚ â˜‘ Increased dyspnea                                       â”‚
â”‚ â˜‘ Increased sputum purulence                              â”‚
â”‚ â˜ Increased sputum volume                                 â”‚
â”‚                                                           â”‚
â”‚ TYPE I EXACERBATION â†’ Antibiotics indicated               â”‚
â”‚ Consider NIV if acidotic (pH <7.35) but alert             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Card 1 â€“ Static Assessment/Severity Classification

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ SEVERITY CLASSIFICATION & ASSESSMENT                        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ASTHMA SEVERITY (GINA 2023):                               â”‚
â”‚ â€¢ Mild: PEFR >70%, normal speech, mild wheeze              â”‚
â”‚ â€¢ Moderate: PEFR 40-69%, phrases only, loud wheeze         â”‚
â”‚ â€¢ Severe: PEFR <40%, words only, accessory muscles         â”‚
â”‚ â€¢ Life-threatening: PEFR <25%, silent chest, cyanosis      â”‚
â”‚                                                           â”‚
â”‚ COPD EXACERBATION TYPES (Anthonisen Criteria):            â”‚
â”‚ â€¢ Type I: All 3 symptoms (dyspnea, purulence, volume)      â”‚
â”‚ â€¢ Type II: 2 of 3 symptoms                                â”‚
â”‚ â€¢ Type III: 1 symptom + URI/fever/wheeze                  â”‚
â”‚                                                           â”‚
â”‚ COMMON TRIGGERS:                                           â”‚
â”‚ â€¢ Viral upper respiratory infections (#1 cause)            â”‚
â”‚ â€¢ Allergens (pollen, dust mites, pets)                    â”‚
â”‚ â€¢ Environmental factors (cold air, pollution, smoke)       â”‚
â”‚ â€¢ Medications (NSAIDs, beta-blockers, ACE inhibitors)     â”‚
â”‚ â€¢ Exercise, stress, GERD                                   â”‚
â”‚                                                           â”‚
â”‚ RED FLAGS (High-Risk Features):                            â”‚
â”‚ â€¢ Previous ICU admission or intubation                     â”‚
â”‚ â€¢ â‰¥3 ED visits or â‰¥2 hospitalizations in past year        â”‚
â”‚ â€¢ Current/recent oral steroid use                          â”‚
â”‚ â€¢ Poor medication compliance or technique                  â”‚
â”‚ â€¢ Psychiatric comorbidities                               â”‚
â”‚ â€¢ Food allergy (especially nuts, shellfish)               â”‚
â”‚                                                           â”‚
â”‚ COPD vs ASTHMA DIFFERENTIATION:                            â”‚
â”‚ â€¢ COPD: Older, smoking history, daily symptoms, less reversibleâ”‚
â”‚ â€¢ Asthma: Younger, allergic history, episodic, more reversibleâ”‚
â”‚ â€¢ Mixed: Asthma-COPD overlap (ACO) - treat as both        â”‚
â”‚                                                           â”‚
â”‚ HYPERCAPNIC RESPIRATORY FAILURE: pH <7.35, PaCO2 >45 mmHg â”‚
â”‚ Consider NIV (BiPAP) before intubation in appropriate patientsâ”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Card 2 â€“ Static Physical Exam/Medications

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ PHYSICAL EXAM & MEDICATIONS                                 â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ FOCUSED EXAMINATION:                                       â”‚
â”‚ â€¢ Vitals: Tachypnea >25, tachycardia, pulsus paradoxus >10mmHgâ”‚
â”‚ â€¢ General: Accessory muscle use, unable to lie flat        â”‚
â”‚ â€¢ Pulmonary: Wheeze (loud early, quiet late), decreased    â”‚
â”‚   air movement, prolonged expiratory phase                â”‚
â”‚ â€¢ Cardiac: Tachycardia, distant heart sounds if hyperinflatedâ”‚
â”‚                                                           â”‚
â”‚ ğŸ’¨ BRONCHODILATORS:                                        â”‚
â”‚ â€¢ Albuterol: 2.5-5mg nebulized q20min x3, then q1-4h      â”‚
â”‚   Continuous: 10-15mg/hr for severe exacerbations         â”‚
â”‚ â€¢ Ipratropium: 0.5mg nebulized q20min x3 (with albuterol) â”‚
â”‚   Then q4-6h, synergistic effect with beta-agonists       â”‚
â”‚ â€¢ Levalbuterol: 1.25-2.5mg neb (if tachycardia concern)   â”‚
â”‚                                                           â”‚
â”‚ ğŸ’Š CORTICOSTEROIDS:                                        â”‚
â”‚ â€¢ Methylprednisolone: 125mg IV initially, then 40-60mg q6h â”‚
â”‚ â€¢ Prednisolone: 40-50mg PO daily x 5-7 days (oral option) â”‚
â”‚ â€¢ No taper required for courses <2 weeks                   â”‚
â”‚                                                           â”‚
â”‚ ğŸ’Š ADJUNCTIVE TREATMENTS:                                  â”‚
â”‚ â€¢ Magnesium sulfate: 2g IV over 20 minutes (severe asthma) â”‚
â”‚   Monitor for hypotension, respiratory depression          â”‚
â”‚ â€¢ Heliox: 70:30 or 80:20 mix (if available)               â”‚
â”‚   Reduces work of breathing, buys time                     â”‚
â”‚                                                           â”‚
â”‚ ğŸ’Š COPD-SPECIFIC TREATMENTS:                               â”‚
â”‚ â€¢ Controlled oxygen: Target SpO2 88-92% (not 94-98%)      â”‚
â”‚ â€¢ Antibiotics (Type I/II exacerbations): Azithromycin     â”‚
â”‚   500mg daily x 3 days OR Amoxicillin-clavulanate         â”‚
â”‚ â€¢ Aminophylline: Loading 5mg/kg IV, then 0.5mg/kg/hr      â”‚
â”‚   (Only if severe, monitor levels and toxicity)           â”‚
â”‚                                                           â”‚
â”‚ MONITORING: Peak flow q2-4h, continuous SpO2, cardiac     â”‚
â”‚ monitoring, reassess response q30min initially            â”‚
â”‚                                                           â”‚
â”‚ ESCALATION: NIV for hypercapnic failure, intubation for   â”‚
â”‚ exhaustion, altered mental status, silent chest, arrest   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

## FLOWCHART (Bottom Panel â€“ Mermaid Algorithm)

```mermaid
graph TD
    A[Acute Asthma/COPD Exacerbation]
    B[O2 plus Nebs plus Steroids]
    C[Assess in 30-60 min]
    D{Response to Treatment?}
    E[Continue Nebs q4h]
    F[Increase Frequency plus Add Mg]
    G[Continuous Nebs plus Consider NIV]
    H[Reassess in 2-4h]
    I{Improving?}
    J{Better Response?}
    K[Continue Aggressive Rx]
    L[ICU plus Intubation]
    M{PEFR >70% or Stable?}
    N[Discharge Planning]
    O[Admit for Monitoring]

    A --> B
    B --> C
    C --> D
    D -- Good --> E
    D -- Partial --> F
    D -- Poor --> G
    E --> H
    F --> I
    I -- Yes --> E
    I -- No --> G
    G --> J
    J -- Yes --> K
    J -- No --> L
    H --> M
    M -- Yes --> N
    M -- No --> O
    K --> H
```

## INTERACTIVE ELEMENTS

### Peak Flow Response Tracker
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚       PEAK FLOW MONITORING SYSTEM       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ Patient: 28yo F | Baseline: 450 L/min   â”‚
â”‚                                         â”‚
â”‚ TIME    PEFR   % PREDICTED  TREATMENT   â”‚
â”‚ 14:00   180    40% (Severe) Initial nebsâ”‚
â”‚ 14:30   220    49%          2nd round   â”‚
â”‚ 15:00   280    62%          Continue    â”‚
â”‚ 15:30   320    71% âœ“        Improving   â”‚
â”‚ 16:00   350    78% âœ“        Stable      â”‚
â”‚                                         â”‚
â”‚ TREND: â†— CONSISTENTLY IMPROVING          â”‚
â”‚                                         â”‚
â”‚ DISCHARGE CRITERIA:                     â”‚
â”‚ â˜‘ PEFR >70% predicted (320 L/min)       â”‚
â”‚ â˜‘ O2 saturation >92% on room air        â”‚
â”‚ â˜‘ Speaking in full sentences            â”‚
â”‚ â˜ No accessory muscle use               â”‚
â”‚ â˜ Minimal/no wheeze                     â”‚
â”‚                                         â”‚
â”‚ STATUS: Meeting criteria for discharge   â”‚
â”‚                                         â”‚
â”‚ [UPDATE PEFR] [ASSESS SYMPTOMS]         â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Severity Score Calculator
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚    ASTHMA EXACERBATION SEVERITY SCORE   â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ INITIAL ASSESSMENT:                     â”‚
â”‚                                         â”‚
â”‚ Speech pattern:                         â”‚
â”‚ â— Phrases only (2 points)               â”‚
â”‚                                         â”‚
â”‚ Position preference:                    â”‚
â”‚ â— Sitting upright (1 point)             â”‚
â”‚                                         â”‚
â”‚ Wheeze character:                       â”‚
â”‚ â— Loud bilateral wheeze (2 points)      â”‚
â”‚                                         â”‚
â”‚ Accessory muscle use:                   â”‚
â”‚ â— Present throughout (2 points)         â”‚
â”‚                                         â”‚
â”‚ Peak flow (% predicted):                â”‚
â”‚ â— 40% predicted (2 points)              â”‚
â”‚                                         â”‚
â”‚ TOTAL INITIAL SCORE: 9/10 (SEVERE)      â”‚
â”‚                                         â”‚
â”‚ AFTER TREATMENT (1 hour):               â”‚
â”‚ Speech: Full sentences (0 pts)          â”‚
â”‚ Position: Can lie back (0 pts)          â”‚
â”‚ Wheeze: Mild expiratory (1 pt)          â”‚
â”‚ Accessory muscles: Minimal (1 pt)       â”‚
â”‚ Peak flow: 71% predicted (0 pts)        â”‚
â”‚                                         â”‚
â”‚ POST-TREATMENT SCORE: 2/10 (MILD)       â”‚
â”‚                                         â”‚
â”‚ RESPONSE: EXCELLENT                     â”‚
â”‚ Plan: Transition to discharge planning   â”‚
â”‚                                         â”‚
â”‚ [RECALCULATE] [TREND ANALYSIS]          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### COPD Exacerbation Assessment
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚    COPD EXACERBATION CLASSIFICATION     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ANTHONISEN CRITERIA:                    â”‚
â”‚                                         â”‚
â”‚ Major Symptoms:                         â”‚
â”‚ â˜‘ Increased dyspnea (baseline â†’ severe) â”‚
â”‚ â˜‘ Increased sputum purulence (yellow)   â”‚
â”‚ â˜ Increased sputum volume               â”‚
â”‚                                         â”‚
â”‚ Minor Symptoms:                         â”‚
â”‚ â˜‘ Upper respiratory infection           â”‚
â”‚ â˜ Fever >38Â°C                          â”‚
â”‚ â˜‘ Increased wheeze                      â”‚
â”‚ â˜ Increased cough                       â”‚
â”‚                                         â”‚
â”‚ CLASSIFICATION: TYPE I (2+ major)       â”‚
â”‚                                         â”‚
â”‚ ANTIBIOTIC INDICATION: YES              â”‚
â”‚ Recommended: Azithromycin 500mg x 3d    â”‚
â”‚ Alternative: Amoxicillin-clavulanate    â”‚
â”‚                                         â”‚
â”‚ SEVERITY MARKERS:                       â”‚
â”‚ â€¢ Home O2 dependent: Yes                â”‚
â”‚ â€¢ FEV1 <50%: Yes (35% predicted)        â”‚
â”‚ â€¢ Frequent exacerbations: 3/year        â”‚
â”‚                                         â”‚
â”‚ PROGNOSIS: Moderate-high risk           â”‚
â”‚ Consider NIV if pH 7.25-7.35            â”‚
â”‚                                         â”‚
â”‚ [ANTIBIOTIC ORDERS] [NIV ASSESSMENT]    â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Discharge Readiness Checklist
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚      ASTHMA DISCHARGE CRITERIA          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ CLINICAL STABILITY:                     â”‚
â”‚ â˜‘ PEFR >70% personal best (350/450)     â”‚
â”‚ â˜‘ O2 saturation >92% on room air        â”‚
â”‚ â˜‘ No accessory muscle use               â”‚
â”‚ â˜‘ Speaking in full sentences            â”‚
â”‚ â˜‘ Minimal/no wheeze on exam             â”‚
â”‚                                         â”‚
â”‚ MEDICATION OPTIMIZATION:                â”‚
â”‚ â˜‘ Prednisolone 40mg PO x 5 days         â”‚
â”‚ â˜‘ Albuterol MDI + spacer demonstrated   â”‚
â”‚ â˜‘ Controller therapy restarted          â”‚
â”‚   (Fluticasone/salmeterol 250/25 BID)   â”‚
â”‚                                         â”‚
â”‚ PATIENT EDUCATION COMPLETED:            â”‚
â”‚ â˜‘ Trigger identification and avoidance  â”‚
â”‚ â˜‘ Written asthma action plan reviewed   â”‚
â”‚ â˜‘ Proper inhaler technique confirmed    â”‚
â”‚ â˜‘ When to seek emergency care           â”‚
â”‚                                         â”‚
â”‚ FOLLOW-UP ARRANGEMENTS:                 â”‚
â”‚ â˜‘ Primary care in 48-72 hours           â”‚
â”‚ â˜‘ Pulmonology within 2 weeks            â”‚
â”‚ â˜‘ Return precautions given              â”‚
â”‚                                         â”‚
â”‚ OVERALL STATUS: âœ… READY FOR DISCHARGE   â”‚
â”‚                                         â”‚
â”‚ [PRINT DISCHARGE SUMMARY] [Rx ORDERS]   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

## VIRTUA VOORHEES ASTHMA/COPD EXACERBATION ADDENDA

- **Respiratory Therapy Services:** 24/7 RT coverage with nebulizer protocols, BiPAP initiation, and continuous albuterol capabilities
- **Pulmonology Consultation:** Available via Transfer Center 856-886-5111 for severe exacerbations and discharge planning
- **Pharmacy Integration:** Medication reconciliation, inhaler technique education, and adherence counseling
- **Quality Metrics:** Time to first bronchodilator, appropriate steroid use, readmission rates within 30 days

## REFERENCE (GUIDELINE & SOURCE)
Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2023.  
https://ginasthma.org/2023-gina-main-report/

**Additional References:**  
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of COPD, 2023 Report.  
https://goldcopd.org/2023-gold-report-2/

British Thoracic Society/Scottish Intercollegiate Guidelines Network. 2019 British Guideline on the Management of Asthma.  
https://www.brit-thoracic.org.uk/quality-improvement/guidelines/asthma/

Anthonisen NR, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987.  
https://www.acpjournals.org/doi/10.7326/0003-4819-106-2-196

**All steps follow current evidence-based guidelines for asthma and COPD exacerbation management with integrated severity assessment tools, peak flow monitoring, and optimized bronchodilator and corticosteroid protocols for both conditions.**
